ramosetron has been researched along with epirubicin in 1 studies
| Studies (ramosetron) | Trials (ramosetron) | Recent Studies (post-2010) (ramosetron) | Studies (epirubicin) | Trials (epirubicin) | Recent Studies (post-2010) (epirubicin) |
|---|---|---|---|---|---|
| 194 | 94 | 83 | 5,453 | 1,838 | 1,570 |
| Protein | Taxonomy | ramosetron (IC50) | epirubicin (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.75 | ||
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K | 1 |
1 trial(s) available for ramosetron and epirubicin
| Article | Year |
|---|---|
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Appetite; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Nausea; Safety; Serotonin Antagonists; Treatment Outcome; Vomiting | 1999 |